850252-34-5

Basic information

• Product Name: [402960-19-4],C9H18N2O2, 186.40
• Synonyms: (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxaMido)acetaMido)-3,3-diMethylbutanoyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid;HexanaMide,3-aMino-N-cyclopropyl-2-hydroxy-, hydrochloride (1:1);vx950 intermediate;Telaprevir INT3;Hexanamide,3-amino-N-cyclopropyl-2-hydroxy-,monohydrochloride,(3S)-(9CI);3-amino-N-cycloPropyl-2-hydroxy-;[402960-19-4],C9H18N2O2, 186.40;Hexanamide, 3-amino-N-cycloPropyl-2-hydroxy-
• CAS NO: 850252-34-5
• Molecular Formula: C₉H₁₈N₂O₂*ClH
• Molecular Weight: 222.71236
• EINECS: 1312995-182-4
• Product Categories: API
• Mol File: 850252-34-5.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: [402960-19-4],C9H18N2O2, 186.40(CAS DataBase Reference)
• NIST Chemistry Reference: [402960-19-4],C9H18N2O2, 186.40(850252-34-5)
• EPA Substance Registry System: [402960-19-4],C9H18N2O2, 186.40(850252-34-5)

Safety Data

• Hazardous Substances Data: 850252-34-5(Hazardous Substances Data)

Usage

General Description

The chemical with the CAS number [402960-19-4] has the molecular formula C9H18N2O2 and a molar mass of 186.40 g/mol. It is likely a organic compound consisting of carbon, hydrogen, nitrogen, and oxygen atoms. The specific properties and uses of this chemical are not provided in the given information. However, based on its molecular formula, it can be inferred that the chemical may have applications in various industries such as pharmaceuticals, agrochemicals, or materials science. Further information about its structure and properties would be needed to fully understand its potential uses and effects.

Upstream product

• 944716-71-6 (2S,3S)-N-cyclopropyl-3-(tert-butoxycarbonyl)amino-2-hydroxyhexanoic acid amide 
• 856707-38-5 acetic acid (2S)-2-tert-butoxycarbonylamino-1-cyclopropylcarbamoylpentyl ester 
• 160801-73-0 (S)-tert-butyl 1-(methoxy(methyl)amino)-1-oxopentan-2-ylcarbamate 
• 160801-74-1 (2S)-2-(1,1-dimethylethoxycarbonylamino)pentanal 
• 53308-95-5 N-tert-butoxycarbonyl-L-norvaline 
• 856707-39-6 (3S,3S)-N-cyclopropyl-3-(tert-butoxycarbonyl)amino-2-hydroxyhexanoic acid amide 

Downstream Products

• 402959-36-8 (1S,3aR,6aS)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-[(2-pyrazinylcarbonyl)amino] acetyl]amino]-3,3-dimethylbutanoyl]-N-[(1S)-1-[(cyclopropylamino)(hydroxy)acetyl]butyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide 
• 856707-40-9 C₃₆H₅₅N₇O₆ 
• 865469-70-1 C₃₃H₅₅N₅O₇S 
• 865469-57-4 C₃₅H₆₁N₅O₉S 
• 856707-67-0 C₃₆H₆₁N₅O₇ 
• 856707-62-5 C₃₇H₅₆N₆O₆ 
• 850251-51-3 pyrazine-2-carboxylic acid [(1-{4-(5-chloro-pyridin-2-yloxy)-2-[1-(cyclopropylcarbamoyl-hydroxy-methyl)-butylcarbamoyl]-pyrrolidine-1-carbonyl}-2,2-dimethyl-propylcarbamoyl)-cyclohexyl-methyl]-amide 

Relevant articles and documents

Discovery of narlaprevir (SCH 900518): A potent, second generation HCV NS3 serine protease inhibitor

Boceprevir (SCH 503034), 1, a novel HCV NS3 serine protease inhibitor discovered in our laboratories, is currently undergoing phase III clinical trials. Detailed investigations toward a second generation protease inhibitor culminated in the discovery of narlaprevir (SCH 900518), 37, with improved potency (～10-fold over 1), pharmacokinetic profile and physicochemical characteristics, currently in phase II human trials. Exploration of synthetic sequence for preparation of 37 resulted in a route that required no silica gel purification for the entire synthesis.

Inhibitors of hepatitis C virus NS3/4A: α-Ketoamide based macrocyclic inhibitors

A novel series of hepatitis C virus (HCV) NS3/4A protease inhibitors bearing a P2-P4 macrocycle and a P1-P1′ α-ketoamide serine trap is reported. The NS3 protease, which is essential for viral replication, is considered one of the most attractive targets

HCV INHIBITORS

The present invention is directed to compounds that are antiviral agents. Specifically, the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.